China News Online, March 11 (Reporter Chen Jing) Moderate to severe atopic dermatitis (AD) is a refractory systemic immune disease. Repeated episodes of intense itching and skin rashes plague patients. To effective control, or cause anxiety and depression.
The reporter learned on the 11th that Shanghai is the first to explore the establishment of a treatment center for atopic dermatitis to provide patients with standardized diagnosis and treatment, while increasing the awareness of the disease and promoting the overall treatment of atopic dermatitis.
Professor Ding Yangfeng told reporters that the diagnosis rate of the disease is low and it is easy to be confused with ordinary eczema.
Photo courtesy of Shanghai Dermatology Hospital
During the interview, the reporter learned that in the past 30 years, the prevalence of atopic dermatitis has gradually increased, showing a situation of high incidence and low diagnosis.
Clinically, many atopic dermatitis are misdiagnosed as eczema, refractory eczema, and chronic eczema, and many patients underestimate the severity of the disease.
In fact, atopic dermatitis is different from general skin diseases, and the treatment plan is also very different. If the patient's diagnosis and treatment are not timely and irregular, it is easy to cause recurrent episodes of the disease.
It is reported that the atopic dermatitis diagnosis and treatment center was listed at the Shanghai Dermatology Hospital that day.
Professor Li Bin, Dean of Shanghai Dermatology Hospital, said in an interview that the establishment of the atopic dermatitis diagnosis and treatment center has groundbreaking value in China and will help patients with atopic dermatitis achieve long-term standardized full-course treatment.
According to reports, in the future, more "standardized diagnosis and treatment centers for atopic dermatitis" will be launched in Shanghai and across the country.
Professor Ding Yangfeng, director of the Department of Dermatology of the hospital, told reporters that the diagnosis rate of the disease is low and it is easy to be confused with ordinary eczema, and the lack of professional talents in the diagnosis and treatment of atopic dermatitis by dermatologists has caused many patients to be underdiagnosed.
Professor Shi Yuling, deputy dean of the Shanghai Dermatology Hospital, introduced: “Patients with atopic dermatitis need long-term standardized management and start standardized treatment as soon as possible. In the atopic dermatitis diagnosis and treatment center, patients can achieve'screening and evaluation' before treatment. After the continuous'follow-up education', we can obtain more professional, standardized and scientific diagnosis and treatment." The expert told reporters that atopic dermatitis requires full-cycle management.
The Atopic Dermatitis Diagnosis and Treatment Center will also help both doctors and patients use the innovative AD Cloud Butler (PDA) tool to realize long-term disease management by doctors and help patients achieve good long-term control.
Professor Yuling Shi introduced that patients with atopic dermatitis need long-term standardized management and standardized treatment as soon as possible.
Photo courtesy of Shanghai Dermatology Hospital
It is understood that with the launch of innovative drugs, Chinese patients have ushered in new treatment options. Professor Ding Yangfeng introduced that before the advent of biological agents, the treatment of atopic dermatitis was limited and the effect of controlling symptoms such as itching was not good. From March 1st, according to the national medical insurance drug catalog adjustment, Dabituo? Become the only targeted biological agent in the new medical insurance catalog for the treatment of moderate to severe atopic dermatitis. In this regard, Professor Zhu Quangang, director of the Department of Pharmacy of Shanghai Dermatology Hospital, believes: "Innovative drug Dabitol? Included in the national medical insurance catalogue meets the urgent needs of patients with atopic dermatitis for breakthrough innovative drugs and strengthens patients’ long-term medication compliance. It plays a vital role in promoting the overall treatment level of atopic dermatitis in China.” (End)